Melexis Reports Q1 Sales Ahead of Forecasts, Maintains H1 Guidance By Investing.com

Melexis reported Q1 revenue of €202 million, slightly above the €199 million consensus, while EBIT margin of 16.4% also beat estimates. EPS of €0.57 missed the €0.62 forecast, and the company maintained H1 guidance for sales roughly in line with last year and gross margin around 40%. Management expects Q2 revenue of about €208 million versus €211 million expected, though it said China automotive demand is stabilizing and European demand remains healthy.

Analysis

This print looks like a classic low-volatility “good enough” update rather than an inflection point: the key message is that the China auto channel is no longer a source of downside, which matters more for sentiment than the modest revenue beat. For an analog auto supplier, the second-order effect is that inventory destocking is probably done, so the next leg is driven by underlying vehicle build rates rather than channel normalization. That usually improves forecast confidence first, then multiples, which means the stock can re-rate before earnings power visibly accelerates.

The bigger read-through is competitive: if European demand is still holding while China stabilizes, suppliers with heavier China exposure and weaker industrial end-markets are the ones that should underperform on relative guidance. Melexis’ conservative H1 framing suggests management is protecting against a soft Q4 rather than seeing broad deterioration; that typically implies the market is underestimating 2H leverage if auto production stays flat-to-up. The capex number also signals discipline, which should support free cash flow conversion and limit downside in a macro wobble.

The contrarian risk is that this is a “stabilization, not acceleration” story, so consensus may be anchoring too aggressively to sequential improvement. If Europe rolls over or Chinese OEM pricing pressure intensifies, the mix benefit disappears quickly and the stock becomes a low-growth value trap. The main catalyst window is the next 6-10 weeks, when order visibility into Q3 should translate into either a cleaner upgrade cycle or renewed skepticism on the back half.

From a trading standpoint, the setup favors relative-value over outright direction: the stock can work if auto semis remain in a range, but the upside is capped until 2H inflects. The risk/reward is best if entered on post-earnings consolidation rather than chasing the initial reaction, because the market will likely want proof that margin stability is durable before paying up.

Key Decisions for Investors

• Initiate a tactical long in MLXS on weakness over the next 1-2 weeks, targeting a 5-8% rebound if Q3 visibility improves; stop if commentary turns cautious on Europe or China pricing.
• Pair trade: long MLXS / short a more cyclical auto-semiconductor peer with greater China beta over the next 1-2 months to isolate the stabilization premium; expect 200-300 bps of relative outperformance if auto builds hold.
• Use call spreads rather than stock for MLXS into the next update cycle: buy 3-6 month calls and sell higher strikes to capture a modest re-rating with limited premium outlay; best if implied vol is not too rich.
• Reduce exposure to names levered to auto semiconductor end-demand but lacking balance-sheet discipline; Melexis’ capex restraint and margin hold suggest the market will reward free-cash-flow quality over pure top-line beta.